Microbix announces new flu vax subsidiary

Toronto-based Microbix Biosystems has created a subsidiary to support its flu vaccine business, including a deal with China's Hunan Biopharmaceutical. The new company, Crucible International Biotechnologies, is valued at C$14 million, which will help finance a new production building.

Microbix will also transfer its Virusmax production technology to Crucible, which should double vaccine production. In 2008, the company entered an agreement with Hunan to create the world's third largest vaccine production facility, capable of creating 120 million doses each year.

- check out Reuters' story

Suggested Articles

Despite the setback, Fulcrum hailed the data as “very encouraging,” zeroing in on results from a pre-specified sensitivity analysis to make its case.

Bayer has struck a $425 million upfront deal to buy KaNDy in the belief its treatment for menopause-related hot flashes has blockbuster potential.

After its recent $4.8 billion buyout of gene therapy specialist Spark Therapeutics, Roche is now handing over one of its execs as its CMO.